Cyberounds Logo
June 16, 2019 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Insulin Therapy for Type 2 Diabetes
CME credit is no longer available for this conference.
Eli Ipp, M.D.

In the past three years, Dr. Ipp has received grant/research support from Pfizer, Inc., R.W. Johnson, and Novo-Nordisk. He has served as a consultant for Novo-Nordisk, SmithKline Beecham Pharmaceutical and Hoechst Marion Roussel. Dr Ipp has also served on the Speakers' Bureau for Novo-Nordisk.


Release Date: 04/16/2000
Termination Date: 04/16/2003

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Discuss the difficulties encountered in switching type 2 diabetic patients to insulin
  • List the indications for insulin therapy in type 2 diabetes
  • Discuss the different insulins available for treatment of type 2 diabetes
  • Discuss combination therapy with oral agents and insulin in type 2 diabetes.

 
This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity